196 results on '"Pellier, Isabelle"'
Search Results
2. Determinants of long-term outcomes of splenectomy in pediatric autoimmune cytopenias
- Author
-
Pincez, Thomas, Aladjidi, Nathalie, Héritier, Sébastien, Garnier, Nathalie, Fahd, Mony, Abou Chahla, Wadih, Fernandes, Helder, Dichamp, Claire, Ducassou, Stéphane, Pasquet, Marlène, Bayart, Sophie, Moshous, Despina, Cheikh, Nathalie, Paillard, Catherine, Plantaz, Dominique, Jeziorski, Eric, Thomas, Caroline, Guitton, Corinne, Deparis, Marianna, Marie Cardine, Aude, Stephan, Jean-Louis, Pellier, Isabelle, Doré, Eric, Benadiba, Joy, Pluchart, Claire, Briandet, Claire, Barlogis, Vincent, Leverger, Guy, and Leblanc, Thierry
- Published
- 2022
- Full Text
- View/download PDF
3. Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome
- Author
-
Pincez, Thomas, primary, Fernandes, Helder, additional, Fahd, Mony, additional, Pasquet, Marlène, additional, Chahla, Wadih Abou, additional, Granel, Jérome, additional, Ducassou, Stéphane, additional, Thomas, Caroline, additional, Garnier, Nathalie, additional, Jeziorski, Eric, additional, Bayart, Sophie, additional, Chastagner, Pascal, additional, Cheikh, Nathalie, additional, Guitton, Corinne, additional, Paillard, Catherine, additional, Lejeune, Julien, additional, Millot, Frédéric, additional, Li‐Thiao Te, Valérie, additional, Mallebranche, Coralie, additional, Pellier, Isabelle, additional, Castelle, Martin, additional, Armari‐Alla, Corinne, additional, Carausu, Liana, additional, Piguet, Christophe, additional, Benadiba, Joy, additional, Pluchart, Claire, additional, Stephan, Jean‐Louis, additional, Deparis, Marianna, additional, Briandet, Claire, additional, Doré, Eric, additional, Marie‐Cardine, Aude, additional, Barlogis, Vincent, additional, Leverger, Guy, additional, Héritier, Sébastien, additional, Aladjidi, Nathalie, additional, and Leblanc, Thierry, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
- Author
-
Brangier, Antoine, Codron, Philippe, Lemée, Jean Michel, Pichon, Virginie, Dhersin, Robin, Urbanski, Geoffrey, Lavigne, Christian, Courtois, Roxane, Danielou, Hélène, Lebreton, Jonathan, Vatan, Rémi, Crochette, Nicolas, Lainé, Jean-Baptiste, Perez, Lucia, Blanchi, Sophie, Hitoto, Hikombo, Bernard, Louis, Maillot, François, Marchand Adam, Sylvain, Talarmin, Jean-Philippe, Gaigneux, Emeline, Motte-Vincent, Pauline, Morrier, Marine, Merrien, Dominique, Bleher, Yves, Flori, Maxime, Ducet-Boiffard, Amélie, Colin, Orane, Février, Ronan, Thill, Pauline, Tetart, Macha, Demaeght, François, Lafond-Desmurs, Barthelemy, Pradier, Maxime, Meybeck, Agnes, Picaud, Marjorie, Prazuck, Thierry, Chapelet, Guillaume, Rouaud, Agnès, Le Turnier, Paul, Sunder, Simon, Lorleac'h, Aurélien, Dollon, Christophe, Jacquet, Antoine, Le Vely, Francois, Gazeau, Pierre, Ansart, Séverine, Roger, Hélène, Laterza, François, Buzelé, Rodolphe, Tahmi, Fella, Lepeule, Raphael, Lacombe, Karine, Lefebvre, Bénédicte, Célarier, Thomas, Gagneux-Brunon, Amandine, Botelho-Nevers, Elisabeth, Bernard, Marc, Garnier, Camille, Mourguet, Morgane, Pugnet, Gregory, Vienne-Noyes, Sara, Martin-Blondel, Guillaume, Delobel, Pierre, Grouteau, Gaspard, Debard, Alexa, Guilleminault, Laurent, Arias, Pauline, Chakvetadze, Catherine, Flateau, Clara, Kopp, Aude, Putot, Alain, Barben, Jeremy, Mouries Martin, Suzanne, Nuss, Valentine, Piroth, Lionel, Claessens, Yann-Erick, Hentgen, Veronique, Martinot, Martin, Bach-Bunner, Maxime, Bonijoly, Thomas, Gravier, Simon, Michel, Jean-Marc, Andreu, Mathilde, Roriz, Mélanie, Baldolli, Aurélie, Brochard, Julia, Grossi, Olivier, Pineau, Samuel, Brisset, Josselin, Desvaux, Edouard, Gondran, Guillaume, Faucher, Jean-François, Quesnel, Paul-Antoine, Bezanahary, Holy, Danthu, Clément, Gutierrez, Blandine, Ly, Kim, Simonneau, Yannick, Cypierre, Anne, Pinet, Pauline, Durox, Hélène, Ducroix-Roubertou, Sophie, Genet, Claire, Beraud, Guillaume, Le Moal, Gwenael, Rammaert, Blandine, Lanoix, Jean-Philippe, Andrejak, Claire, Joseph, Cédric, Soriot-Thomas, Sandrine, Dhote, Robin, Abad, Sébastien, Benainous, Ruben, Boitiaux, Jean-François, Briend, Guillaume, Gonfroy, Celine, Harent, Stanislas, Lagrange, Aurore, Tone, Alina, Wayenberg, Laura, Desoutter, Sophie, Ettahar, Nicolas, Gey, Thomas, Leroy, Vincent, Gaillard, Sacha, Toma, Andrea, Broussier, Amaury, Etienne, Sandrine, Spivac, Yann, Martha, Benoit, Roch, Nathalie, Diaz, Pierre, N’guyen Baranoff, Danièle, Rebaudet, Stanislas, Jourda, François, Zeller, Valérie, Bienvenu, Boris, Boyer, Arnaud, Pellier, Isabelle, Mercat, Alain, Darsonval, Astrid, Blanchet, Odile, Custaud, Marc-Antoine, Lefeuvre, Caroline, Parot-Schinkel, Elsa, Vielle, Bruno, Briet, Marie, Roy, Pierre-Marie, Dubée, Vincent, Guidet, Bertrand, Mismetti, Patrick, Vicaut, Eric, Sanchez, Olivier, Girard, Philippe, Elias, Antoine, Couturaud, Francis, Gable, Béatrice, Lazareff, Sybille, Carballido, Loïc, Hue, Catherine, Chrétien, Jean-Marie, Goraguer, Adrien, Eeckhoutte, Lucie van, Abbara, Chadi, Boucher, Sophie, Devaud, Edouard, Robineau, Olivier, Rispal, Patrick, Guimard, Thomas, d’Anglejean, Emma, and Diamantis, Sylvain
- Published
- 2021
- Full Text
- View/download PDF
5. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival
- Author
-
Cluster B, Immuno/reuma patientenzorg, Child Health, Infection & Immunity, Vallée, Tanja C., Glasmacher, Jannik S., Buchner, Hannes, Arkwright, Peter D., Behrends, Uta, Bondarenko, Anastasia, Browning, Michael J., Buchbinder, David, Cattoni, Alessandro, Chernyshova, Liudmyla, Ciznar, Peter, Cole, Theresa, Czogała, Wojciech, Dueckers, Gregor, Edgar, John David M., Erbey, Fatih, Fasth, Anders, Ferrua, Francesca, Formankova, Renata, Gambineri, Eleonora, Gennery, Andrew R., Goldman, Frederick D., Gonzalez-Granado, Luis I., Heilmann, Carsten, Heiskanen-Kosma, Tarja, Juntti, Hanna, Kainulainen, Leena, Kanegane, Hirokazu, Karaca, Neslihan E., Kilic, Sara S., Klein, Christoph, Kołtan, Sylwia, Kondratenko, Irina, Meyts, Isabelle, Nasrullayeva, Gulnara M., Notarangelo, Lucia D., Pasic, Srdjan, Pellier, Isabelle, Pignata, Claudio, Misbah, Siraj, Schulz, Ansgar, Segundo, Gesmar R., Shcherbina, Anna, Slatter, Mary, Sokolic, Robert, Soler-Palacin, Pere, Stepensky, Polina, van Montfrans, Joris M., Ryhänen, Samppa, Wolska-Kuśnierz, Beata, Ziegler, John B., Zhao, Xiaodong, Aiuti, Alessandro, Ochs, Hans D., Albert, Michael H., Cluster B, Immuno/reuma patientenzorg, Child Health, Infection & Immunity, Vallée, Tanja C., Glasmacher, Jannik S., Buchner, Hannes, Arkwright, Peter D., Behrends, Uta, Bondarenko, Anastasia, Browning, Michael J., Buchbinder, David, Cattoni, Alessandro, Chernyshova, Liudmyla, Ciznar, Peter, Cole, Theresa, Czogała, Wojciech, Dueckers, Gregor, Edgar, John David M., Erbey, Fatih, Fasth, Anders, Ferrua, Francesca, Formankova, Renata, Gambineri, Eleonora, Gennery, Andrew R., Goldman, Frederick D., Gonzalez-Granado, Luis I., Heilmann, Carsten, Heiskanen-Kosma, Tarja, Juntti, Hanna, Kainulainen, Leena, Kanegane, Hirokazu, Karaca, Neslihan E., Kilic, Sara S., Klein, Christoph, Kołtan, Sylwia, Kondratenko, Irina, Meyts, Isabelle, Nasrullayeva, Gulnara M., Notarangelo, Lucia D., Pasic, Srdjan, Pellier, Isabelle, Pignata, Claudio, Misbah, Siraj, Schulz, Ansgar, Segundo, Gesmar R., Shcherbina, Anna, Slatter, Mary, Sokolic, Robert, Soler-Palacin, Pere, Stepensky, Polina, van Montfrans, Joris M., Ryhänen, Samppa, Wolska-Kuśnierz, Beata, Ziegler, John B., Zhao, Xiaodong, Aiuti, Alessandro, Ochs, Hans D., and Albert, Michael H.
- Published
- 2024
6. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival
- Author
-
Vallée, T, Glasmacher, J, Buchner, H, Arkwright, P, Behrends, U, Bondarenko, A, Browning, M, Buchbinder, D, Cattoni, A, Chernyshova, L, Ciznar, P, Cole, T, Czogala, W, Dueckers, G, Edgar, J, Erbey, F, Fasth, A, Ferrua, F, Formankova, R, Gambineri, E, Gennery, A, Goldman, F, Gonzalez-Granado, L, Heilmann, C, Heiskanen-Kosma, T, Juntti, H, Kainulainen, L, Kanegane, H, Karaca, N, Sebnem Kilic, S, Klein, C, Koltan, S, Kondratenko, I, Meyts, I, Nasrullayeva, G, Notarangelo, L, Pasic, S, Pellier, I, Pignata, C, Misbah, S, Schulz, A, Segundo, G, Shcherbina, A, Slatter, M, Sokolic, R, Soler-Palacin, P, Stepensky, P, van Montfrans, J, Ryhänen, S, Wolska-Kuśnierz, B, Ziegler, J, Zhao, X, Aiuti, A, Ochs, H, Albert, M, Vallée, Tanja C, Glasmacher, Jannik S, Buchner, Hannes, Arkwright, Peter D, Behrends, Uta, Bondarenko, Anastasia, Browning, Michael J, Buchbinder, David K, Cattoni, Alessandro, Chernyshova, Liudmyla, Ciznar, Peter, Cole, Theresa, Czogala, Wojciech, Dueckers, Gregor, Edgar, John David M, Erbey, Fatih, Fasth, Anders, Ferrua, Francesca, Formankova, Renata, Gambineri, Eleonora, Gennery, Andrew R, Goldman, Frederick D, Gonzalez-Granado, Luis Ignacio, Heilmann, Carsten, Heiskanen-Kosma, Tarja, Juntti, Hanna, Kainulainen, Leena, Kanegane, Hirokazu, Karaca, Neslihan E., Sebnem Kilic, Sara, Klein, Christoph, Koltan, Sylwia, Kondratenko, Irina, Meyts, Isabelle, Nasrullayeva, Gulnara M, Notarangelo, Lucia Dora, Pasic, Srdjan, Pellier, Isabelle, Pignata, Claudio, Misbah, Siraj Ahmed, Schulz, Ansgar S, Segundo, Gesmar RS, Shcherbina, Anna, Slatter, Mary A, Sokolic, Robert, Soler-Palacin, Pere, Stepensky, Polina, van Montfrans, Joris M., Ryhänen, Samppa, Wolska-Kuśnierz, Beata, Ziegler, John B, Zhao, Xiaodong, Aiuti, Alessandro, Ochs, Hans D, Albert, Michael H, Vallée, T, Glasmacher, J, Buchner, H, Arkwright, P, Behrends, U, Bondarenko, A, Browning, M, Buchbinder, D, Cattoni, A, Chernyshova, L, Ciznar, P, Cole, T, Czogala, W, Dueckers, G, Edgar, J, Erbey, F, Fasth, A, Ferrua, F, Formankova, R, Gambineri, E, Gennery, A, Goldman, F, Gonzalez-Granado, L, Heilmann, C, Heiskanen-Kosma, T, Juntti, H, Kainulainen, L, Kanegane, H, Karaca, N, Sebnem Kilic, S, Klein, C, Koltan, S, Kondratenko, I, Meyts, I, Nasrullayeva, G, Notarangelo, L, Pasic, S, Pellier, I, Pignata, C, Misbah, S, Schulz, A, Segundo, G, Shcherbina, A, Slatter, M, Sokolic, R, Soler-Palacin, P, Stepensky, P, van Montfrans, J, Ryhänen, S, Wolska-Kuśnierz, B, Ziegler, J, Zhao, X, Aiuti, A, Ochs, H, Albert, M, Vallée, Tanja C, Glasmacher, Jannik S, Buchner, Hannes, Arkwright, Peter D, Behrends, Uta, Bondarenko, Anastasia, Browning, Michael J, Buchbinder, David K, Cattoni, Alessandro, Chernyshova, Liudmyla, Ciznar, Peter, Cole, Theresa, Czogala, Wojciech, Dueckers, Gregor, Edgar, John David M, Erbey, Fatih, Fasth, Anders, Ferrua, Francesca, Formankova, Renata, Gambineri, Eleonora, Gennery, Andrew R, Goldman, Frederick D, Gonzalez-Granado, Luis Ignacio, Heilmann, Carsten, Heiskanen-Kosma, Tarja, Juntti, Hanna, Kainulainen, Leena, Kanegane, Hirokazu, Karaca, Neslihan E., Sebnem Kilic, Sara, Klein, Christoph, Koltan, Sylwia, Kondratenko, Irina, Meyts, Isabelle, Nasrullayeva, Gulnara M, Notarangelo, Lucia Dora, Pasic, Srdjan, Pellier, Isabelle, Pignata, Claudio, Misbah, Siraj Ahmed, Schulz, Ansgar S, Segundo, Gesmar RS, Shcherbina, Anna, Slatter, Mary A, Sokolic, Robert, Soler-Palacin, Pere, Stepensky, Polina, van Montfrans, Joris M., Ryhänen, Samppa, Wolska-Kuśnierz, Beata, Ziegler, John B, Zhao, Xiaodong, Aiuti, Alessandro, Ochs, Hans D, and Albert, Michael H
- Abstract
Wiskott-Aldrich syndrome (WAS) is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.9 years (range, 0.3-71.1), totaling 6118 patient-years, were included in this international retrospective study. Overall survival (OS) of the cohort (censored at HSCT or GT) was 82% (95% confidence interval, 78-87) at age 15 years and 70% (61-80) at 30 years. The type of variant was predictive of outcome: patients with a missense variant in exons 1 or 2 or with the intronic hot spot variant c.559+5G>A (class I variants) had a 15-year OS of 93% (89-98) and a 30-year OS of 91% (86-97), compared with 71% (62-81) and 48% (34-68) in patients with any other variant (class II; P < .0001). The cumulative incidence rates of disease-related complications such as severe bleeding (P = .007), life-threatening infection (P < .0001), and autoimmunity (P = .004) occurred significantly later in patients with a class I variant. The cumulative incidence of malignancy (P = .6) was not different between classes I and II. It confirms the spectrum of disease severity and quantifies the risk for specific disease-related complications. The class of the variant is a biomarker to predict the outcome for patients with WAS.
- Published
- 2024
7. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes
- Author
-
Hadjadj, Jérôme, Aladjidi, Nathalie, Fernandes, Helder, Leverger, Guy, Magérus-Chatinet, Aude, Mazerolles, Fabienne, Stolzenberg, Marie-Claude, Jacques, Sidonie, Picard, Capucine, Rosain, Jérémie, Fourrage, Cécile, Hanein, Sylvain, Zarhrate, Mohammed, Pasquet, Marlène, Abou Chahla, Wadih, Barlogis, Vincent, Bertrand, Yves, Pellier, Isabelle, Colomb Bottollier, Elodie, Fouyssac, Fanny, Blouin, Pascale, Thomas, Caroline, Cheikh, Nathalie, Dore, Eric, Pondarre, Corinne, Plantaz, Dominique, Jeziorski, Eric, Millot, Frédéric, Garcelon, Nicolas, Ducassou, Stéphane, Perel, Yves, Leblanc, Thierry, Neven, Bénédicte, Fischer, Alain, and Rieux-Laucat, Frédéric
- Published
- 2019
- Full Text
- View/download PDF
8. MAGT1 deficiency in XMEN disease is associated with severe platelet dysfunction and impaired platelet glycoprotein N-glycosylation
- Author
-
Kauskot, Alexandre, primary, Mallebranche, Coralie, additional, Bruneel, Arnaud, additional, Fenaille, François, additional, Solarz, Jean, additional, Viellard, Toscane, additional, Feng, Miao, additional, Repérant, Christelle, additional, Bordet, Jean-Claude, additional, Cholet, Sophie, additional, Denis, Cécile V., additional, McCluskey, Geneviève, additional, Latour, Sylvain, additional, Martin, Emmanuel, additional, Pellier, Isabelle, additional, Lasne, Dominique, additional, Borgel, Delphine, additional, Kracker, Sven, additional, Ziegler, Alban, additional, Tuffigo, Marie, additional, Fournier, Benjamin, additional, Miot, Charline, additional, and Adam, Frédéric, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Prediction of the Clinical Course of Immune Thrombocytopenia in Children by Platelet Kinetics
- Author
-
Lejeune, Julien, primary, Raoult, Violette, additional, Dubrasquet, Mathilde, additional, Chauvin, Romane, additional, Mallebranche, Coralie, additional, Pellier, Isabelle, additional, Monceaux, Françoise, additional, Bayart, Sophie, additional, Grain, Audrey, additional, Gyan, Emmanuel, additional, Ravalet, Noémie, additional, Herault, Olivier, additional, and Ternant, David, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond–like syndrome
- Author
-
Bellanné-Chantelot, Christine, Schmaltz-Panneau, Barbara, Marty, Caroline, Fenneteau, Odile, Callebaut, Isabelle, Clauin, Séverine, Docet, Aurélie, Damaj, Gandhi-Laurent, Leblanc, Thierry, Pellier, Isabelle, Stoven, Cécile, Souquere, Sylvie, Antony-Debré, Iléana, Beaupain, Blandine, Aladjidi, Nathalie, Barlogis, Vincent, Bauduer, Frédéric, Bensaid, Philippe, Boespflug-Tanguy, Odile, Berger, Claire, Bertrand, Yves, Carausu, Liana, Fieschi, Claire, Galambrun, Claire, Schmidt, Aline, Journel, Hubert, Mazingue, Françoise, Nelken, Brigitte, Quah, Thuan Chong, Oksenhendler, Eric, Ouachée, Marie, Pasquet, Marlène, Saada, Véronique, Suarez, Felipe, Pierron, Gérard, Vainchenker, William, Plo, Isabelle, and Donadieu, Jean
- Published
- 2018
- Full Text
- View/download PDF
11. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients
- Author
-
Bluteau, Olivier, Sebert, Marie, Leblanc, Thierry, Peffault de Latour, Régis, Quentin, Samuel, Lainey, Elodie, Hernandez, Lucie, Dalle, Jean-Hugues, Sicre de Fontbrune, Flore, Lengline, Etienne, Itzykson, Raphael, Clappier, Emmanuelle, Boissel, Nicolas, Vasquez, Nadia, Da Costa, Mélanie, Masliah-Planchon, Julien, Cuccuini, Wendy, Raimbault, Anna, De Jaegere, Louis, Adès, Lionel, Fenaux, Pierre, Maury, Sébastien, Schmitt, Claudine, Muller, Marc, Domenech, Carine, Blin, Nicolas, Bruno, Bénédicte, Pellier, Isabelle, Hunault, Mathilde, Blanche, Stéphane, Petit, Arnaud, Leverger, Guy, Michel, Gérard, Bertrand, Yves, Baruchel, André, Socié, Gérard, and Soulier, Jean
- Published
- 2018
- Full Text
- View/download PDF
12. Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations
- Author
-
Miot, Charline, Imai, Kohsuke, Imai, Chihaya, Mancini, Anthony J., Kucuk, Zeynep Yesim, Kawai, Tokomki, Nishikomori, Ryuta, Ito, Etsuro, Pellier, Isabelle, Dupuis Girod, Sophie, Rosain, Jeremie, Sasaki, Shinya, Chandrakasan, Shanmuganathan, Pachlopnik Schmid, Jana, Okano, Tsubasa, Colin, Estelle, Olaya-Vargas, Alberto, Yamazaki-Nakashimada, Marco, Qasim, Waseem, Espinosa Padilla, Sara, Jones, Andrea, Krol, Alfons, Cole, Nyree, Jolles, Stephen, Bleesing, Jack, Vraetz, Thomas, Gennery, Andrew R., Abinun, Mario, Güngör, Tayfun, Costa-Carvalho, Beatriz, Condino-Neto, Antonio, Veys, Paul, Holland, Steven M., Uzel, Gulbu, Moshous, Despina, Neven, Benedicte, Blanche, Stéphane, Ehl, Stephan, Döffinger, Rainer, Patel, Smita Y., Puel, Anne, Bustamante, Jacinta, Gelfand, Erwin W., Casanova, Jean-Laurent, Orange, Jordan S., and Picard, Capucine
- Published
- 2017
- Full Text
- View/download PDF
13. Depicting the genetic architecture of pediatric cancers through an integrative gene network approach
- Author
-
Savary, Clara, Kim, Artem, Lespagnol, Alexandra, Gandemer, Virginie, Pellier, Isabelle, Andrieu, Charlotte, Pagès, Gilles, Galibert, Marie-Dominique, Blum, Yuna, and de Tayrac, Marie
- Published
- 2020
- Full Text
- View/download PDF
14. Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population.
- Author
-
Faust, Cindy, Auquier, Pascal, Gandemer, Virginie, Bertrand, Yves, Tabone, Marie‐Dominique, Ansoborlo, Sophie, Baruchel, André, Bonneau, Jacinthe, Dalle, Jean‐Hugues, Chastagner, Pascal, Kanold, Justyna, Poirée, Maryline, Theron, Alexandre, Olivier, Laura, Pellier, Isabelle, Michel, Gérard, and Berbis, Julie
- Subjects
EDUCATIONAL outcomes ,ADULT child abuse victims ,SIBLINGS ,HEMATOPOIETIC stem cells ,GRADE repetition ,STEM cell donors ,BENCH press - Abstract
Background: To investigate the educational outcomes of siblings of childhood leukemia survivors, explore determinants of school difficulties, and compare the rates of repeating grades between siblings and the general population. Methods: A cross‐sectional study of childhood leukemia survivors' siblings recruited through the Leucémies de l'Enfant et de l'Adolescent cohort, a French long‐term follow‐up program, was conducted, and education‐related data were obtained via self‐report questionnaires. Adjusted logistic regression models were used to identify variables associated with school difficulties and time since diagnosis. Rates of repeating a grade in middle school were compared between siblings and the general population of the same generation. Results: A total of 564 siblings with a mean time from diagnosis of 14.1 ± 6.4 years were included, among whom 139 (24.6%) repeated a grade, at an average of 6.4 ± 4.5 years after diagnosis. In multivariate analysis, the risk factors for repeating a grade were older siblings (odds ratio [OR] 2.3, p = 0.006), family financial difficulties (OR 2.8, p = 0.008), and history of repetition in survivors (OR, 2.5, p = 0.001). Sibling hematopoietic stem cell donors were at greater risk of repeating a grade long‐term after diagnosis (p = 0.018). Overall, siblings did not have a higher risk of educational delays at the end of middle school than the general population. Conclusion: Although the results are reassuring, socioeconomic and cancer‐related factors may have an impact on siblings' schooling long after diagnosis. Paying attention to siblings contributes to identifying the most vulnerable families, allowing more attention and appropriate resources to avoid long‐term repercussions. Additionally, supportive and targeted interventions can be developed to improve the organization of education and the health care system. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The Impact of Donor Type on Long-Term Health Status and Quality of Life after Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia: A Leucémie de l'Enfant et de L'Adolescent Study
- Author
-
Visentin, Sandrine, Auquier, Pascal, Bertrand, Yves, Baruchel, André, Tabone, Marie-Dominique, Pochon, Cécile, Jubert, Charlotte, Poirée, Maryline, Gandemer, Virginie, Sirvent, Anne, Bonneau, Jacinthe, Paillard, Catherine, Freycon, Claire, Kanold, Justyna, Villes, Virginie, Berbis, Julie, Oudin, Claire, Galambrun, Claire, Pellier, Isabelle, Plat, Geneviève, Chambost, Hervé, Leverger, Guy, Dalle, Jean-Hugues, and Michel, Gérard
- Published
- 2016
- Full Text
- View/download PDF
16. Keep in Mind Quality of Life: Outcome of a Ten-Year Series of Post-Transplantation Early Relapses in Childhood Acute Lymphoblastic Leukemia—A Report from the Grand Ouest Oncology Study Group for Children in France
- Author
-
Haro, Sophie, Tavenard, Aude, Rialland, Fanny, Taque, Sophie, Guillerm, Gaelle, Blouin, Pascale, Esvan, Maxime, Pellier, Isabelle, and Gandemer, Virginie
- Published
- 2016
- Full Text
- View/download PDF
17. Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia
- Author
-
Pincez, Thomas, primary, Fernandes, Helder, additional, Pasquet, Marlène, additional, Abou Chahla, Wadih, additional, Granel, Jérome, additional, Héritier, Sébastien, additional, Fahd, Mony, additional, Ducassou, Stéphane, additional, Thomas, Caroline, additional, Garnier, Nathalie, additional, Barlogis, Vincent, additional, Jeziorski, Eric, additional, Bayart, Sophie, additional, Chastagner, Pascal, additional, Cheikh, Nathalie, additional, Guitton, Corinne, additional, Paillard, Catherine, additional, Lejeune, Julien, additional, Millot, Frédéric, additional, Li‐Thiao Te, Valérie, additional, Mallebranche, Coralie, additional, Pellier, Isabelle, additional, Neven, Bénédicte, additional, Armari‐Alla, Corinne, additional, Carausu, Liana, additional, Piguet, Christophe, additional, Benadiba, Joy, additional, Pluchart, Claire, additional, Stephan, Jean‐Louis, additional, Deparis, Marianna, additional, Briandet, Claire, additional, Doré, Eric, additional, Marie‐Cardine, Aude, additional, Leblanc, Thierry, additional, Leverger, Guy, additional, and Aladjidi, Nathalie, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Identification of novel compound heterozygous variants in the SLC30A7 (ZNT7) gene in two French brothers with stunted growth, testicular hypoplasia and bone marrow failure
- Author
-
Huang, Liping, primary, Yang, Zhongyue, additional, Kirschke, Catherine P, additional, Prouteau, Clément, additional, Copin, Marie-Christine, additional, Bonneau, Dominique, additional, Pellier, Isabelle, additional, Coutant, Régis, additional, Miot, Charline, additional, and Ziegler, Alban, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Inborn errors of OAS–RNase L in SARS-CoV-2–related multisystem inflammatory syndrome in children
- Author
-
Lee, Danyel, Le Pen, Jérémie, Yatim, Ahmad, Dong, Beihua, Aquino, Yann, Ogishi, Masato, Pescarmona, Rémi, Talouarn, Estelle, Rinchai, Darawan, Zhang, Peng, Perret, Magali, Liu, Zhiyong, Jordan, Iolanda, Elmas Bozdemir, Sefika, Bayhan, Gulsum Iclal, Beaufils, Camille, Bizien, Lucy, Bisiaux, Aurelie, Lei, Weite, Hasan, Milena, Chen, Jie, Gaughan, Christina, Asthana, Abhishek, Libri, Valentina, Luna, Joseph, Jaffré, Fabrice, Hoffmann, H.-Heinrich, Michailidis, Eleftherios, Moreews, Marion, Seeleuthner, Yoann, Bilguvar, Kaya, Mane, Shrikant, Flores, Carlos, Zhang, Yu, Arias, Andrés, Bailey, Rasheed, Schlüter, Agatha, Milisavljevic, Baptiste, Bigio, Benedetta, Le Voyer, Tom, Materna, Marie, Gervais, Adrian, Moncada-Velez, Marcela, Pala, Francesca, Lazarov, Tomi, Levy, Romain, Neehus, Anna-Lena, Rosain, Jérémie, Peel, Jessica, Chan, Yi-Hao, Morin, Marie-Paule, Pino-Ramirez, Rosa Maria, Belkaya, Serkan, Lorenzo, Lazaro, Anton, Jordi, Delafontaine, Selket, Toubiana, Julie, Bajolle, Fanny, Fumadó, Victoria, Dediego, Marta, Fidouh, Nadhira, Rozenberg, Flore, Pérez-Tur, Jordi, Chen, Shuibing, Evans, Todd, Geissmann, Frédéric, Lebon, Pierre, Weiss, Susan, Bonnet, Damien, Duval, Xavier, Pan-Hammarström, Qiang, Planas, Anna, Meyts, Isabelle, Haerynck, Filomeen, Pujol, Aurora, Sancho-Shimizu, Vanessa, Dalgard, Clifford, Bustamante, Jacinta, Puel, Anne, Boisson-Dupuis, Stéphanie, Boisson, Bertrand, Maniatis, Tom, Zhang, Qian, Bastard, Paul, Notarangelo, Luigi, Béziat, Vivien, Perez de Diego, Rebeca, Rodriguez-Gallego, Carlos, Su, Helen, Lifton, Richard, Jouanguy, Emmanuelle, Cobat, Aurélie, Alsina, Laia, Keles, Sevgi, Haddad, Elie, Abel, Laurent, Belot, Alexandre, Quintana-Murci, Lluis, Rice, Charles, Silverman, Robert, Zhang, Shen-Ying, Casanova, Jean-Laurent, Alavoine, Loubna, Behillil, Sylvie, Burdet, Charles, Charpentier, Charlotte, Dechanet, Aline, Descamps, Diane, Ecobichon, Jean-Luc, Enouf, Vincent, Frezouls, Wahiba, Houhou, Nadhira, Kafif, Ouifiya, Lehacaut, Jonathan, Letrou, Sophie, Lina, Bruno, Lucet, Jean-Christophe, Manchon, Pauline, Nouroudine, Mariama, Piquard, Valentine, Quintin, Caroline, Thy, Michael, Tubiana, Sarah, van der Werf, Sylvie, Vignali, Valérie, Visseaux, Benoit, Yazdanpanah, Yazdan, Chahine, Abir, Waucquier, Nawal, Migaud, Maria-Claire, Deplanque, Dominique, Djossou, Félix, Mergeay-Fabre, Mayka, Lucarelli, Aude, Demar, Magalie, Bruneau, Léa, Gérardin, Patrick, Maillot, Adrien, Payet, Christine, Laviolle, Bruno, Laine, Fabrice, Paris, Christophe, Desille-Dugast, Mireille, Fouchard, Julie, Malvy, Denis, Nguyen, Duc, Pistone, Thierry, Perreau, Pauline, Gissot, Valérie, Le Goas, Carole, Montagne, Samatha, Richard, Lucie, Chirouze, Catherine, Bouiller, Kévin, Desmarets, Maxime, Meunier, Alexandre, Lefèvre, Benjamin, Jeulin, Hélène, Legrand, Karine, Lomazzi, Sandra, Tardy, Bernard, Gagneux-Brunon, Amandine, Bertholon, Frédérique, Botelho-Nevers, Elisabeth, Christelle, Kouakam, Nicolas, Leturque, Roufai, Layidé, Amat, Karine, Couffin-Cadiergues, Sandrine, Espérou, Hélène, Hendou, Samia, Abolhassani, Hassan, Aguilera-Albesa, Sergio, Aiuti, Alessandro, Akcan, Ozge Metin, Akcay, Nihal, Alkan, Gulsum, Alkhater, Suzan, Allende, Luis Miguel, Alper, Yosunkaya, Amenzoui, Naima, Anderson, Mark, Arkin, Lisa, Aubart, Melodie, Avramenko, Iryna, Aydemir, Şehnaz, Gayretli Aydin, Zeynep Gökçe, Aytekin, Caner, Aytekin, Gökhan, Erol Aytekin, Selma, Bando, Silvia Yumi, Beland, Kathie, Biggs, Catherine, Bilbao Aburto, Agurtzane, Blanchard-Rohner, Geraldine, Blázquez-Gamero, Daniel, Bloomfield, Marketa, Bogunovic, Dusan, Bondarenko, Anastasia, Borghesi, Alessandro, Bousfiha, Amed Aziz, Boyarchuk, Oksana, Brodin, Petter, Bryceson, Yenan, Bucciol, Giorgia, Calcaterra, Valeria, Casari, Giorgio, Cavalcanti, Andre, Celik, Jale Bengi, Chrousos, George, Colobran, Roger, Condino-Neto, Antonio, Conti, Francesca, Cooper, Megan, Coskuner, Taner, Cyrus, Cyril, D’auria, Enza, Drolet, Beth, Bursal Duramaz, Burcu, El Zein, Loubna, Elnagdy, Marwa, Emiroglu, Melike, Erdeniz, Emine Hafize, Fabi, Marianna, Baris Feldman, Hagit, Fellay, Jacques, Fencl, Filip, Filippatos, Filippos, Freiss, Julie, Fremuth, Jiri, Gagro, Alenka, Garcia-Solis, Blanca, Vergine, Gianluca, González-Montelongo, Rafaela, Gul, Yahya, Gülhan, Belgin, Gultekin, Sara Sebnem Kilic, Gut, Marta, Halwani, Rabih, Hammarström, Lennart, Hatipoğlu, Nevin, Heath, James, Henrickson, Sarah, Hernandez-Brito, Elisa, Hoffman, Ilse, Hoste, Levi, Hsieh, Elena, Íñigo-Campos, Antonio, Itan, Yuval, Jabandziev, Petr, Kandemir, Bahar, Kanık-Yüksek, Saliha, Kapakli, Hasan, Karbuz, Adem, Kasapcopur, Ozgur, Kechiche, Robin, Kendir Demirkol, Yasemin, Kilic, Omer, Hansen, Stella Kim, Klocperk, Adam, Lau, Yu-Lung, Lebl, Jan, Lorenzo-Salazar, José, Lucas, Carrie, Maglorius, Majistor, Marque, Laura, Novoa Medina, Yeray, Montesdeoca Melián, Abián, Mentis, Alexios-Fotios, Pato, Michele, Michos, Athanasios, Milner, Joshua, Mogensen, Trine, Muñoz-Barrera, Adrián, Nepesov, Serdar, Farela Neves, João, Ng, Ashley, Ng, Lisa, Novelli, Antonio, Novelli, Giuseppe, Oz, Fatma Nur, Ocejo-Viñals, J. Gonzalo, Okada, Satoshi, Orbak, Zerrin, Kilic, Ahmet Osman, Ouair, Hind, Öz, Şadiye Kübra Tüter, Özçelik, Tayfun, Özkan, Esra Akyüz, Parlakay, Aslınur Özkaya, Pato, Carlos, Paz-Artal, Estela, Pelham, Simon, Pellier, Isabelle, Philippot, Quentin, Planas-Serra, Laura, Plassart, Samira, Pokorna, Petra, Polat, Meltem, Poli, Cecilia, Prando, Carolina, Renia, Laurent, Rivière, Jacques, Rodríguez-Palmero, Agustí, Roussel, Lucie, Rubio-Rodriguez, Luis, Salifu, Moro, Sasek, Lumir, Sasia, Laura, Scherbina, Anna, Schmitt, Erica, Sediva, Anna, Sevketoglu, Esra, Slaba, Katerina, Slaby, Ondrej, Sobh, Ali, Solé-Violán, Jordi, Soler-Palacin, Pere, de Somer, Lien, Sözeri, Betül, Spaan, András, Stepanovskiy, Yuriy, Tangye, Stuart, Tanir, Gonul, Tatsi, Elizabeth Barbara, Thorball, Christian, Hancerli Torun, Selda, Turvey, Stuart, Uddin, Mohammed, Uyar, Emel, Valencia-Ramos, Juan, van den Rym, Ana Maria, Vatansev, Hulya, Castillo de Vera, Martín, Vermeulen, François, Vinh, Donald, Volokha, Alla, von Bernuth, Horst, Wouters, Carine, Yahşi, Aysun, Yarar, Volkan, Yesilbas, Osman, Yıldız, Mehmet, Zatz, Mayana, Zawadzki, Pawel, Zuccotti, Gianvincenzo, Rockefeller University [New York], Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Génomique évolutive, modélisation et santé (GEMS), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de référence des rhumatismes inflammatoires et maladies auto-immunes systémiques rares de l’enfant / National Referee Centre for Rheumatic and AutoImmune and Systemic Diseases in Children [Lyon] (RAISE), Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Génétique Physiologie et Systèmes d'Elevage (GenPhySE ), Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-École nationale supérieure agronomique de Toulouse (ENSAT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Sidra Medicine [Doha, Qatar], BIOASTER Technology Research Institute, Lyon, France, St. Giles Laboratory of Human Genetics of Infectious Diseases, Department of Paediatrics and Intensive Care, Hospital Universitari Sant Joan de Deu, Human genetics of infectious diseases : Mendelian predisposition (Equipe Inserm U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique Evolutive Humaine - Human Evolutionary Genetics, Centre de Recherche Translationnelle - Center for Translational Science (CRT), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Shanghai Jiaotong University, Sheffield Hallam University, Institut Jean Lamour (IJL), Institut de Chimie du CNRS (INC)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biodiversité et Epidémiologie des Bactéries pathogènes - Biodiversity and Epidemiology of Bacterial Pathogens, Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 (CIC Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Investigation Clinique de La Réunion - INSERM (CIC 1410), Université de La Réunion (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the 'Investments for the Future' program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21-RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence 'Integrative Biology of Emerging Infectious Diseases' (ANR-10-LABX-62-IBEID) and 'Milieu Intérieur' (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1, AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and 'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19'). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M.P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA. A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444, a George Mason University Fast Grant, the G. Harold and Leila Y. Mathers Charitable Foundation, the Meyer Foundation, and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018)., ANR-10-IAHU-0001,Imagine,Institut Hospitalo-Universitaire Imagine(2010), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), ANR-21-COVR-0039,GenMIS-C,Recherche des Déficits immunitaires innées monogéniques prédisposant au syndrome inflammatoire multisystémique chez l'enfant.(2021), ANR-20-CE93-0003,GENVIR,Analyse multi-omique de l'immunité anti-virale: de l'identification des circuits biologiques pertinents à la découverte de défauts monogéniques héréditaires de l'immunité chez les patients avec infections virales sévères(2020), ANR-20-CO11-0001,AABIFNCOV,Bases génétiques et immunologiques des auto-anticorps contre les interférons de type I prédisposant aux formes sévères de COVID-19.(2020), ANR-21-RHUS-0008,COVIFERON,Covid-19 and interferons: from discovery to therapy(2021), ANR-10-LABX-0069,MILIEU INTERIEUR,GENETIC & ENVIRONMENTAL CONTROL OF IMMUNE PHENOTYPE VARIANCE: ESTABLISHING A PATH TOWARDS PERSONALIZED MEDICINE(2010), ANR-21-CO14-0003,COVID-19-POPCELL,Facteurs génétiques et infectieux à l'origine de la variabilité populationnelle de la réponse immunitaire à l'infection par le SARS-CoV-2(2021), European Project: 824110,H2020-INFRAIA-2018-1,EASI-Genomics(2019), European Project: 101057100,UNDINE, Howard Hughes Medical Institute, Rockefeller University, St. Giles Foundation, National Institutes of Health (US), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Fundación Mapfre, Cabildo de Tenerife, Fundació La Marató de TV3, Centro de Investigación Biomédica en Red Enfermedades Raras (España), Consejo Superior de Investigaciones Científicas (España), European Commission, and Pérez-Tur, Jordi
- Subjects
Multidisciplinary ,Settore MED/03 ,[SDV]Life Sciences [q-bio] ,Medicine and Health Sciences ,CoV-Contact Cohort§ - Abstract
62 páginas, 5 figuras, 2 tablas, Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition that follows benign COVID-19. We report autosomal recessive deficiencies of OAS1, OAS2, or RNASEL in five unrelated children with MIS-C. The cytosolic double-stranded RNA (dsRNA)-sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded RNA-degrading ribonuclease L (RNase L). Monocytic cell lines and primary myeloid cells with OAS1, OAS2, or RNase L deficiencies produce excessive amounts of inflammatory cytokines upon dsRNA or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulation. Exogenous 2-5A suppresses cytokine production in OAS1-deficient but not RNase L-deficient cells. Cytokine production in RNase L-deficient cells is impaired by MDA5 or RIG-I deficiency and abolished by mitochondrial antiviral-signaling protein (MAVS) deficiency. Recessive OAS-RNase L deficiencies in these patients unleash the production of SARS-CoV-2-triggered, MAVS-mediated inflammatory cytokines by mononuclear phagocytes, thereby underlying MIS-C, The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10- LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21- RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence “Integrative Biology of Emerging Infectious Diseases” (ANR-10-LABX-62-IBEID) and “Milieu Intérieur” (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M..P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA. A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018).
- Published
- 2023
- Full Text
- View/download PDF
20. Molecular and clinicopathologic characterization of pediatric histiocytoses
- Author
-
HELIAS-RODZEWICZ, Z, DONADIEU, Jean, TERRONES, Nathalie, BARKAOUI, Mohamed-Aziz, LAMBILLIOTTE, ANNE, MOSHOUS, DESPINA, Thomas, Caroline, AZAMOUSH, SABA, PASQUET, MARLENE, MANSUY, LUDOVIC, ALADJIDI, NATHALIE, JEZIORSKI, ERIC, MAREC-BERARDF, PERRINE, GILIBERT-YVET, MARION, SPIEGEL, ALEXANDRA, SAULTIER, PAUL, PELLIER, ISABELLE, PAGNIER, ANNE, PERTUISEL, SOPHIE, POIREE, MARYLINE, BODET, DAMIEN, MILLOT, FREDERIC, IFSAN, FLORENTINA, STEPHANN, JEAN-LOUIS, LERUSTRE, AMAURY, RIGAUD, CHARLOTTE, FILHON, BRUNO, CARAUSU, LIANA, REGUERRE, YVES, KIEFFER, ISABELLE, Brichard, Bénédicte, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, and UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique
- Abstract
Molecular and clinicopathologic characterization of pediatric histiocytoses.
- Published
- 2023
21. Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors
- Author
-
Saultier, Paul, primary, El Riachy, Nour, additional, Bertrand, Yves, additional, Tabone, Marie-Dominique, additional, Leverger, Guy, additional, Dalle, Jean-Hugues, additional, Baruchel, Andre, additional, Pochon, Cecile, additional, Paillard, Catherine, additional, Ducassou, Stephane, additional, Poiree, Marilyne, additional, Plantaz, Dominique, additional, Kanold, Justyna, additional, Gandemer, Virginie, additional, Sirvent, Nicolas, additional, Plat, Genevieve, additional, Pellier, Isabelle, additional, Reguerre, Yves, additional, Thouvenin, Sandrine, additional, Petit, Audrey Françoise, additional, Auquier, Pascal, additional, Berbis, Julie, additional, and Michel, Gerard, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
- Author
-
Sokal, Aurélien, primary, Bastard, Paul, additional, Chappert, Pascal, additional, Barba-Spaeth, Giovanna, additional, Fourati, Slim, additional, Vanderberghe, Alexis, additional, Lagouge-Roussey, Pauline, additional, Meyts, Isabelle, additional, Gervais, Adrian, additional, Bouvier-Alias, Magali, additional, Azzaoui, Imane, additional, Fernández, Ignacio, additional, de la Selle, Andréa, additional, Zhang, Qian, additional, Bizien, Lucy, additional, Pellier, Isabelle, additional, Linglart, Agnès, additional, Rothenbuhler, Anya, additional, Marcoux, Estelle, additional, Anxionnat, Raphael, additional, Cheikh, Nathalie, additional, Léger, Juliane, additional, Amador-Borrero, Blanca, additional, Fouyssac, Fanny, additional, Menut, Vanessa, additional, Goffard, Jean-Christophe, additional, Storey, Caroline, additional, Demily, Caroline, additional, Mallebranche, Coralie, additional, Troya, Jesus, additional, Pujol, Aurora, additional, Zins, Marie, additional, Tiberghien, Pierre, additional, Gray, Paul E., additional, McNaughton, Peter, additional, Sullivan, Anna, additional, Peake, Jane, additional, Levy, Romain, additional, Languille, Laetitia, additional, Rodiguez-Gallego, Carlos, additional, Boisson, Bertrand, additional, Gallien, Sébastien, additional, Neven, Bénédicte, additional, Michel, Marc, additional, Godeau, Bertrand, additional, Abel, Laurent, additional, Rey, Felix A., additional, Weill, Jean-Claude, additional, Reynaud, Claude-Agnès, additional, Tangye, Stuart G., additional, Casanova, Jean-Laurent, additional, and Mahévas, Matthieu, additional
- Published
- 2022
- Full Text
- View/download PDF
23. Brothers and sisters of childhood acute leukemia survivors: Their long‐term quality of life and its determinants
- Author
-
Faust, Cindy, primary, Auquier, Pascal, additional, Hamidou, Zeinab, additional, Bertrand, Yves, additional, Tabone, Marie‐Dominique, additional, Ansoborlo, Sophie, additional, Baruchel, André, additional, Gandemer, Virginie, additional, Dalle, Jean‐Hugues, additional, Chastagner, Pascal, additional, Kanold, Justyna, additional, Poirée, Maryline, additional, Sirvent, Nicolas, additional, Plat, Geneviève, additional, Pellier, Isabelle, additional, Michel, Gérard, additional, and Berbis, Julie, additional
- Published
- 2022
- Full Text
- View/download PDF
24. Molecular and clinicopathologic characterization of pediatric histiocytoses.
- Author
-
Hélias‐Rodzewicz, Zofia, Donadieu, Jean, Terrones, Nathalie, Barkaoui, Mohamed‐Aziz, Lambilliotte, Anne, Moshous, Despina, Thomas, Caroline, Azarnoush, Saba, Pasquet, Marlène, Mansuy, Ludovic, Aladjidi, Nathalie, Jeziorski, Eric, Marec‐Berard, Perrine, Gilibert‐Yvert, Marion, Spiegel, Alexandra, Saultier, Paul, Pellier, Isabelle, Pagnier, Anne, Pertuisel, Sophie, and Poiree, Maryline
- Published
- 2023
- Full Text
- View/download PDF
25. Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome
- Author
-
Mahlaoui, Nizar, Pellier, Isabelle, Mignot, Cécile, Jais, Jean-Philippe, Bilhou-Nabéra, Chrystèle, Moshous, Despina, Neven, Bénédicte, Picard, Capucine, de Saint-Basile, Geneviève, Cavazzana-Calvo, Marina, Blanche, Stéphane, and Fischer, Alain
- Published
- 2013
- Full Text
- View/download PDF
26. Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency
- Author
-
Özçelik, Tayfun, Campbell, Tessa Mollie, Liu, Zhiyong, Zhang, Qian, Moncada-Velez, Marcela, Covill, Laura E., Zhang, Peng, Darazam, Ilad Alavi, Bastard, Paul, Bizien, Lucy, Bucciol, Giorgia, Enoksson, Sara Lind, Jouanguy, Emmanuelle, Karabela, Şemsi Nur, Khan, Taushif, Kendir-Demirkol, Yasemin, Arias, Andres Augusto, Mansouri, Davood, Marits, Per, Marr, Nico, Migeotte, Isabelle, Moens, Leen, Pellier, Isabelle, Sendel, Anton, Shahrooei, Mohammad, Edvard Smith C.I., Vandernoot, Isabelle, Willekens, Karen, Bergman, Peter, Abel, Laurent, Cobat, Aurélie, Casanova, Jean-Laurent, Meyts, Isabelle, Bryceson, Yenan T., and Özçelik, Tayfun
- Abstract
Autosomal recessive IRF7 deficiency was previously reported in three patients with single critical influenza or COVID-19 pneumonia episodes. The patients’ fibroblasts and plasmacytoid dendritic cells produced no detectable type I and III IFNs, except IFN-β. Having discovered four new patients, we describe the genetic, immunological, and clinical features of seven IRF7-deficient patients from six families and five ancestries. Five were homozygous and two were compound heterozygous for IRF7 variants. Patients typically had one episode of pulmonary viral disease. Age at onset was surprisingly broad, from 6 mo to 50 yr (mean age 29 yr). The respiratory viruses implicated included SARS-CoV-2, influenza virus, respiratory syncytial virus, and adenovirus. Serological analyses indicated previous infections with many common viruses. Cellular analyses revealed strong antiviral immunity and expanded populations of influenza-and SARS-CoV-2–specific memory CD4+ and CD8+ Tcells. IRF7-deficient individuals are prone to viral infections of the respiratory tract but are otherwise healthy, potentially due to residual IFN-β and compensatory adaptive immunity. © 2022 Campbell et al.
- Published
- 2022
27. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)
- Author
-
Schmid, Jana Pachlopnik, Canioni, Danielle, Moshous, Despina, Touzot, Fabien, Mahlaoui, Nizar, Hauck, Fabian, Kanegane, Hirokazu, Lopez-Granados, Eduardo, Mejstrikova, Ester, Pellier, Isabelle, Galicier, Lionel, Galambrun, Claire, Barlogis, Vincent, Bordigoni, Pierre, Fourmaintraux, Alain, Hamidou, Mohamed, Dabadie, Alain, Le Deist, Françoise, Haerynck, Filomeen, Ouachée-Chardin, Marie, Rohrlich, Pierre, Stephan, Jean-Louis, Lenoir, Christelle, Rigaud, Stéphanie, Lambert, Nathalie, Milili, Michèle, Schiff, Claudin, Chapel, Helen, Picard, Capucine, de Saint Basile, Geneviève, Blanche, Stéphane, Fischer, Alain, and Latour, Sylvain
- Published
- 2011
- Full Text
- View/download PDF
28. Brothers and sisters of childhood acute leukemia survivors: Their long‐term quality of life and its determinants.
- Author
-
Faust, Cindy, Auquier, Pascal, Hamidou, Zeinab, Bertrand, Yves, Tabone, Marie‐Dominique, Ansoborlo, Sophie, Baruchel, André, Gandemer, Virginie, Dalle, Jean‐Hugues, Chastagner, Pascal, Kanold, Justyna, Poirée, Maryline, Sirvent, Nicolas, Plat, Geneviève, Pellier, Isabelle, Michel, Gérard, and Berbis, Julie
- Subjects
ACUTE leukemia ,QUALITY of life ,SISTERS ,SIBLINGS ,FRENCH people - Abstract
Background: Childhood cancer confront the whole family with a traumatic event. Because brothers and sisters may encounter emotional problems that can remain for a long time and that only few studies have assessed their long‐term outcome, our present objectives were to describe the long‐term quality of life (QoL) of childhood leukemia survivors' siblings and to explore its determinant. Methods: Brothers and sisters (from 8‐year‐old) of survivors included in the French LEA Cohort completed a QoL questionnaire (according to their age). Scores were compared with those reported by age‐ and gender‐matched French general population and by survivors. Using a clustering method, siblings were categorized into 3 groups depending on their level of QoL's scores and factors likely to be linked with these clusters were explored with multivariate analyses. Results: We included 689 brothers and sisters (313 minors, 376 adults) and the mean time from diagnosis was 13.2 ± 6.6 years. Minor siblings reported higher QoL scores than general population (p < 0.001), but a lower score for relationship with family than survivors (p < 0.001). In adult siblings, Mental Component Summary score was lower than general population (p < 0.001). Level of siblings' QoL was linked with female gender, but no association was found with cancer‐related factors. Conclusion: Brothers and sisters expressed a divergent perception of their long‐term QoL depending on their age. To minimize the impact from childhood to adulthood, long‐term attention should also be paid to siblings, often referred as "forgotten children". [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options
- Author
-
Albert, Michael H., Bittner, Tanja C., Nonoyama, Shigeaki, Notarangelo, Lucia Dora, Burns, Siobhan, Imai, Kohsuke, Espanol, Teresa, Fasth, Anders, Pellier, Isabelle, Strauss, Gabriele, Morio, Tomohiro, Gathmann, Benjamin, Noordzij, Jeroen G., Fillat, Cristina, Hoenig, Manfred, Nathrath, Michaela, Meindl, Alfons, Pagel, Philipp, Wintergerst, Uwe, Fischer, Alain, Thrasher, Adrian J., Belohradsky, Bernd H., and Ochs, Hans D.
- Published
- 2010
- Full Text
- View/download PDF
30. Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial
- Author
-
Dubée, Vincent, Roy, Pierre-Marie, Vielle, Bruno, Parot-Schinkel, Elsa, Blanchet, Odile, Darsonval, Astrid, Lefeuvre, Caroline, Abbara, Chadi, Boucher, Sophie, Devaud, Edouard, Robineau, Olivier, Rispal, Patrick, Guimard, Thomas, d’Anglejean, Emma, Diamantis, Sylvain, Custaud, Marc-Antoine, Pellier, Isabelle, and Mercat, Alain
- Subjects
Aged, 80 and over ,hydroxychloroquine ,Critical Care ,SARS-CoV-2 ,COVID-19 ,Middle Aged ,Respiration, Artificial ,Virus Shedding ,COVID-19 Drug Treatment ,Treatment Outcome ,Double-Blind Method ,Risk Factors ,randomized controlled trial ,Humans ,Original Article ,Pandemics ,Aged - Abstract
To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening.We conducted a multicentre randomized double-blind placebo-controlled trial evaluating hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening: need for supplemental oxygen, age ≥75 years, age between 60 and 74 years and presence of at least one co-morbidity. Severely ill patients requiring oxygen therapy3 L/min or intensive care were excluded. Eligible patients were randomized in a 1:1 ratio to receive either 800 mg hydroxychloroquine on day 0 followed by 400 mg per day for 8 days or a placebo. The primary end point was a composite of death or start of invasive mechanical ventilation within 14 days following randomization. Secondary end points included mortality and clinical evolution at days 14 and 28, and viral shedding at days 5 and 10.The trial was stopped after 250 patients were included because of a slowing down of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and hydroxychloroquine groups, respectively. The median age was 77 years (interquartile range 58-86 years) and 151/250 (60.4%) patients required oxygen therapy. The primary end point occurred in 9/124 (7.3%) patients in the hydroxychloroquine group and 8/123 (6.5%) patients in the placebo group (relative risk 1.12; 95% CI 0.45-2.80). The rates of positive SARS-CoV-2 RT-PCR tests at days 5 and 10 were 72.8% (75/103) and 57.1% (52/91) in the hydroxychloroquine group, versus 73.0% (73/100) and 56.6% (47/83) in the placebo group, respectively. No difference was observed between the two groups in any of the other secondary end points.In this underpowered trial involving mainly older patients with mild to moderate COVID-19, patients treated with hydroxychloroquine did not experience better clinical or virological outcomes than those receiving the placebo.ClinicalTrials.gov Identifier: NCT04325893 (https://clinicaltrials.gov/ct2/show/NCT04325893).
- Published
- 2021
31. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
- Author
-
Dubée, Vincent, primary, Roy, Pierre-Marie, additional, Vielle, Bruno, additional, Parot-Schinkel, Elsa, additional, Blanchet, Odile, additional, Darsonval, Astrid, additional, Lefeuvre, Caroline, additional, Abbara, Chadi, additional, Boucher, Sophie, additional, Devaud, Edouard, additional, Robineau, Olivier, additional, Rispal, Patrick, additional, Guimard, Thomas, additional, d’Anglejean, Emma, additional, Diamantis, Sylvain, additional, Custaud, Marc-Antoine, additional, Pellier, Isabelle, additional, Mercat, Alain, additional, Brangier, Antoine, additional, Codron, Philippe, additional, Lemée, Jean Michel, additional, Pichon, Virginie, additional, Dhersin, Robin, additional, Urbanski, Geoffrey, additional, Lavigne, Christian, additional, Courtois, Roxane, additional, Danielou, Hélène, additional, Lebreton, Jonathan, additional, Vatan, Rémi, additional, Crochette, Nicolas, additional, Lainé, Jean-Baptiste, additional, Perez, Lucia, additional, Blanchi, Sophie, additional, Hitoto, Hikombo, additional, Bernard, Louis, additional, Maillot, François, additional, Marchand Adam, Sylvain, additional, Talarmin, Jean-Philippe, additional, Gaigneux, Emeline, additional, Motte-Vincent, Pauline, additional, Morrier, Marine, additional, Merrien, Dominique, additional, Bleher, Yves, additional, Flori, Maxime, additional, Ducet-Boiffard, Amélie, additional, Colin, Orane, additional, Février, Ronan, additional, Thill, Pauline, additional, Tetart, Macha, additional, Demaeght, François, additional, Lafond-Desmurs, Barthelemy, additional, Pradier, Maxime, additional, Meybeck, Agnes, additional, Picaud, Marjorie, additional, Prazuck, Thierry, additional, Chapelet, Guillaume, additional, Rouaud, Agnès, additional, Le Turnier, Paul, additional, Sunder, Simon, additional, Lorleac'h, Aurélien, additional, Dollon, Christophe, additional, Jacquet, Antoine, additional, Le Vely, Francois, additional, Gazeau, Pierre, additional, Ansart, Séverine, additional, Roger, Hélène, additional, Laterza, François, additional, Buzelé, Rodolphe, additional, Tahmi, Fella, additional, Lepeule, Raphael, additional, Lacombe, Karine, additional, Lefebvre, Bénédicte, additional, Célarier, Thomas, additional, Gagneux-Brunon, Amandine, additional, Botelho-Nevers, Elisabeth, additional, Bernard, Marc, additional, Garnier, Camille, additional, Mourguet, Morgane, additional, Pugnet, Gregory, additional, Vienne-Noyes, Sara, additional, Martin-Blondel, Guillaume, additional, Delobel, Pierre, additional, Grouteau, Gaspard, additional, Debard, Alexa, additional, Guilleminault, Laurent, additional, Arias, Pauline, additional, Chakvetadze, Catherine, additional, Flateau, Clara, additional, Kopp, Aude, additional, Putot, Alain, additional, Barben, Jeremy, additional, Mouries Martin, Suzanne, additional, Nuss, Valentine, additional, Piroth, Lionel, additional, Claessens, Yann-Erick, additional, Hentgen, Veronique, additional, Martinot, Martin, additional, Bach-Bunner, Maxime, additional, Bonijoly, Thomas, additional, Gravier, Simon, additional, Michel, Jean-Marc, additional, Andreu, Mathilde, additional, Roriz, Mélanie, additional, Baldolli, Aurélie, additional, Brochard, Julia, additional, Grossi, Olivier, additional, Pineau, Samuel, additional, Brisset, Josselin, additional, Desvaux, Edouard, additional, Gondran, Guillaume, additional, Faucher, Jean-François, additional, Quesnel, Paul-Antoine, additional, Bezanahary, Holy, additional, Danthu, Clément, additional, Gutierrez, Blandine, additional, Ly, Kim, additional, Simonneau, Yannick, additional, Cypierre, Anne, additional, Pinet, Pauline, additional, Durox, Hélène, additional, Ducroix-Roubertou, Sophie, additional, Genet, Claire, additional, Beraud, Guillaume, additional, Le Moal, Gwenael, additional, Rammaert, Blandine, additional, Lanoix, Jean-Philippe, additional, Andrejak, Claire, additional, Joseph, Cédric, additional, Soriot-Thomas, Sandrine, additional, Dhote, Robin, additional, Abad, Sébastien, additional, Benainous, Ruben, additional, Boitiaux, Jean-François, additional, Briend, Guillaume, additional, Gonfroy, Celine, additional, Harent, Stanislas, additional, Lagrange, Aurore, additional, Tone, Alina, additional, Wayenberg, Laura, additional, Desoutter, Sophie, additional, Ettahar, Nicolas, additional, Gey, Thomas, additional, Leroy, Vincent, additional, Gaillard, Sacha, additional, Toma, Andrea, additional, Broussier, Amaury, additional, Etienne, Sandrine, additional, Spivac, Yann, additional, Martha, Benoit, additional, Roch, Nathalie, additional, Diaz, Pierre, additional, N’guyen Baranoff, Danièle, additional, Rebaudet, Stanislas, additional, Jourda, François, additional, Zeller, Valérie, additional, Bienvenu, Boris, additional, Boyer, Arnaud, additional, Briet, Marie, additional, Dubée, Vincent, additional, Guidet, Bertrand, additional, Mismetti, Patrick, additional, Vicaut, Eric, additional, Sanchez, Olivier, additional, Girard, Philippe, additional, Elias, Antoine, additional, Couturaud, Francis, additional, Gable, Béatrice, additional, Lazareff, Sybille, additional, Carballido, Loïc, additional, Hue, Catherine, additional, Chrétien, Jean-Marie, additional, Goraguer, Adrien, additional, and Eeckhoutte, Lucie van, additional
- Published
- 2021
- Full Text
- View/download PDF
32. Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up
- Author
-
Pincez, Thomas, Fernandes, Helder, Leblanc, Thierry, Michel, Gérard, Barlogis, Vincent, Bertrand, Yves, Neven, Bénédicte, Abou Chahla, Wadih, Pasquet, Marlène, Guitton, Corinne, Marie-Cardine, Aude, Pellier, Isabelle, Armari-Alla, Corinne, Benadiba, Joy, Blouin, Pascale, Jeziorski, Eric, Millot, Frederic, Paillard, Catherine, Thomas, Caroline, Cheikh, Nathalie, Bayard, Sophie, Fouyssac, Fanny, Piguet, Christophe, Deparis, Mariana, Briandet, Claire, Doré, Eric, Landman-Parker, Judith, Leverger, Guy, and Aladjidi, Nathalie
- Published
- 2020
- Full Text
- View/download PDF
33. Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency
- Author
-
Coignard-Biehler, Hélène, Mahlaoui, Nizar, Pilmis, Benoît, Barlogis, Vincent, Brosselin, Pauline, de Vergnes, Nathalie, Debré, Marianne, Malphettes, Marion, Frange, Pierre, Catherinot, Emilie, Pellier, Isabelle, Durieu, Isabelle, Perlat, Antoinette, Royer, Bruno, Le Quellec, Alain, Jeziorski, Eric, Fischer, Alain, Lortholary, Olivier, Study Group, Members of The Ceredih French Pid, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Marseille, Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Foch [Suresnes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], Laboratoire d'Hématologie [CHU Amiens], CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Collège de France (CdF (institution)), and Retiveau, Nolwenn
- Subjects
[SDV.IMM] Life Sciences [q-bio]/Immunology ,Immunology ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Immunology and Allergy ,[SDV.IMM]Life Sciences [q-bio]/Immunology - Abstract
International audience; The original version of the article contained error regarding the presentation of the institutional authors in the PDF and html versions.
- Published
- 2020
- Full Text
- View/download PDF
34. Environmental exposures related to parental habits in the perinatal period and the risk of Wilms' tumor in children
- Author
-
Notz-Carrere, Anne, Rios, Paula, Bauer, Helene, Schleiermacher, Gudrun, Pasqualini, Claudia, Boulanger, Cecile, Thébaud, Estelle, Gandemer, Virginie, Pellier, Isabelle, Verschuur, Arnauld, Sudour-Bonnange, Hélène, Coulomb-L'Hermine, Aurore, Spiegel, Alexandra, Notz- Carrere, Anne, Bergeron, Christophe, Orsi, Laurent, Lacour, Brigitte, Clavel, Jacqueline, CHU Bordeaux [Bordeaux], Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Curie [Paris], Université Paris-Saclay, Institut Gustave Roussy (IGR), Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Strasbourg, Centre Léon Bérard [Lyon], INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm), Ligue National Contre le Cancer (LNCC), Fondation de FranceFondation de France, Fondation ARC, Agence nationale de securite sanitaire de l'alimentation, de l'environnement et du travail (ANSES)French National Research Agency (ANR), association Cent pour sang la vie, Agence Nationale de la Recherche (ANR)French National Research Agency (ANR), Institut National du Cancer (INCa)Institut National du Cancer (INCA) France, Canceropole Ile de FranceRegion Ile-de-France, Investment for the future [ANR-10-COHO-0009], ANR-10-COHO-0009,HOPE-EPI,HOPE-Epidémiologie – Recherche épidémiologique en Hémato-Oncologie Pediatrique(2010), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance Publique-Hôpitaux de Marseille (AP-HM), UNICANCER-Université Lille Nord de France (COMUE), Service de pathologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Lille Nord de France (COMUE)-UNICANCER, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and CCA - Cancer Treatment and Quality of Life
- Subjects
Male ,Parents ,Cancer Research ,Etiology ,Epidemiology ,Logistic regression ,[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology ,Habits ,0302 clinical medicine ,Wilms' tumor ,Risk Factors ,Pregnancy ,Medicine ,030212 general & internal medicine ,Child ,education.field_of_study ,Obstetrics ,Confounding ,Smoking ,Case-control study ,Kidney Neoplasms ,3. Good health ,Perinatal Care ,Oncology ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Alcohol ,Childhood cancer ,Adult ,medicine.medical_specialty ,Alcohol Drinking ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Wilms Tumor ,03 medical and health sciences ,Humans ,Pesticides ,education ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,business.industry ,Odds ratio ,Environmental Exposure ,medicine.disease ,Confidence interval ,Case-Control Studies ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
International audience; Introduction Wilms' tumor is the most frequently diagnosed renal tumor in children. Little is known about its etiology. The aim of this study was to investigate the potential role of specific exposures related to parental habits such as parental smoking, maternal alcohol consumption and the use of household pesticides during pregnancy.Methods The ESTELLE study was a nationwide case-control study that included 117 Wilms' tumor cases and 1100 control children from the general French population, frequency-matched by age and gender. Unconditional logistic regression was used to estimate odds ratios and 95 % confidence intervals.Results After controlling for matching variables and potential confounders, the maternal use of any type of pesticide during pregnancy was associated with the risk of Wilms' tumor in children (OR 1.6 [95 % CI 1.1-2.3]). Insecticides were the most commonly reported type of pesticide and there was a positive association with their use (OR 1.7 [95 % CI 1.1-2.6]. The association was stronger when they were used more often than once a month (OR 1.9 [95 % CI 1.2-3.0]. Neither maternal smoking during pregnancy nor paternal smoking during preconception/pregnancy was associated with a risk of Wilms' tumor (ORs 1.1[95 % CI 0.7-1.8] and 1.1 [95 % CI 0.7-1.7], respectively). No association was observed with maternal alcohol intake during pregnancy (OR 1.2 [95 % CI 0.8-2.0]).Conclusion Our findings suggest an association between the maternal use of household pesticides during pregnancy and the risk of Wilms' tumor.
- Published
- 2020
- Full Text
- View/download PDF
35. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection.
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Fournier, Benjamin, Boutboul, David, Bruneau, Julie, Miot, Charline, Boulanger, Cécile, Malphettes, Marion, Pellier, Isabelle, Dunogué, Bertrand, Terrier, Benjamin, Suarez, Felipe, Blanche, Stéphane, Castelle, Martin, Winter, Sarah, Delecluse, Henri-Jacques, Molina, Thierry, Picard, Capucine, Ehl, Stephan, Moshous, Despina, Galicier, Lionel, Barlogis, Vincent, Fischer, Alain, Neven, Bénédicte, Latour, Sylvain, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Fournier, Benjamin, Boutboul, David, Bruneau, Julie, Miot, Charline, Boulanger, Cécile, Malphettes, Marion, Pellier, Isabelle, Dunogué, Bertrand, Terrier, Benjamin, Suarez, Felipe, Blanche, Stéphane, Castelle, Martin, Winter, Sarah, Delecluse, Henri-Jacques, Molina, Thierry, Picard, Capucine, Ehl, Stephan, Moshous, Despina, Galicier, Lionel, Barlogis, Vincent, Fischer, Alain, Neven, Bénédicte, and Latour, Sylvain
- Abstract
Epstein-Barr virus (EBV) preferentially infects epithelial cells and B lymphocytes and sometimes T and NK lymphocytes. Persistence of EBV-infected cells results in severe lymphoproliferative disorders (LPDs). Diagnosis of EBV-driven T or NK cell LPD and chronic active EBV diseases (CAEBV) is difficult, often requiring biopsies. Herein, we report a flow-FISH cytometry assay that detects cells expressing EBV-encoded small RNAs (EBERs), allowing rapid identification of EBV-infected cells among PBMCs. EBV-infected B, T, and/or NK cells were detectable in various LPD conditions. Diagnosis of CAEBV in 22 patients of Caucasian and African origins was established. All exhibited circulating EBV-infected T and/or NK cells, highlighting that CAEBV is not restricted to native American and Asian populations. Proportions of EBV-infected cells correlated with blood EBV loads. We showed that EBV-infected T cells had an effector memory activated phenotype, whereas EBV-infected B cells expressed plasma cell differentiation markers. Thus, this method achieves accurate and unambiguous diagnoses of different forms of EBV-driven LPD and represents a powerful tool to study their pathophysiological mechanisms.
- Published
- 2020
36. Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
- Author
-
Pincez, Thomas, primary, Fernandes, Helder, additional, Leblanc, Thierry, additional, Michel, Gérard, additional, Barlogis, Vincent, additional, Bertrand, Yves, additional, Neven, Bénédicte, additional, Chahla, Wadih Abou, additional, Pasquet, Marlène, additional, Guitton, Corinne, additional, Marie-Cardine, Aude, additional, Pellier, Isabelle, additional, Armari-Alla, Corinne, additional, Benadiba, Joy, additional, Blouin, Pascale, additional, Jeziorski, Eric, additional, Millot, Frédéric, additional, Paillard, Catherine, additional, Thomas, Caroline, additional, Cheikh, Nathalie, additional, Bayart, Sophie, additional, Fouyssac, Fanny, additional, Piguet, Christophe, additional, Deparis, Marianna, additional, Briandet, Claire, additional, Dore, Eric, additional, Picard, Capucine, additional, Rieux-Laucat, Frédéric, additional, Landman-Parker, Judith, additional, Leverger, Guy, additional, and Aladjidi, Nathalie, additional
- Published
- 2021
- Full Text
- View/download PDF
37. HGG-40. EXCEPTIONAL SYNCHRONOUS OCCURENCE OF A BRAF V600E MUTANT GLIOBLASTOMA AND A H3.3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA: A CASE REPORT
- Author
-
De Carli, Emilie, primary, Boisselier, Blandine, additional, Fournier, Luc Le, additional, Supiot, Stéphane, additional, Mallebranche, Coralie, additional, Proust-Houdemont, Stéphanie, additional, Duplan, Mylène, additional, Pellier, Isabelle, additional, and Rousseau, Audrey, additional
- Published
- 2020
- Full Text
- View/download PDF
38. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection
- Author
-
Fournier, Benjamin, primary, Boutboul, David, additional, Bruneau, Julie, additional, Miot, Charline, additional, Boulanger, Cécile, additional, Malphettes, Marion, additional, Pellier, Isabelle, additional, Dunogué, Bertrand, additional, Terrier, Benjamin, additional, Suarez, Felipe, additional, Blanche, Stéphane, additional, Castelle, Martin, additional, Winter, Sarah, additional, Delecluse, Henri-Jacques, additional, Molina, Thierry, additional, Picard, Capucine, additional, Ehl, Stephan, additional, Moshous, Despina, additional, Galicier, Lionel, additional, Barlogis, Vincent, additional, Fischer, Alain, additional, Neven, Bénédicte, additional, and Latour, Sylvain, additional
- Published
- 2020
- Full Text
- View/download PDF
39. MON-098 Risk of Long-Term Endocrine Sequelae in Survivors of Progressing Childhood Optic Pathway Glioma Treated by Upfront Chemotherapy: Preliminary Analyses of 102 Subjects from the French Multicentric BB-SFOP Registry
- Author
-
Hippolyte, Helene, primary, De Carli, Emilie, primary, Pellier, Isabelle, primary, Rialland, Xavier, primary, and Coutant, Regis, primary
- Published
- 2020
- Full Text
- View/download PDF
40. Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis
- Author
-
Moshous, Despina, primary, Briand, Coralie, primary, Castelle, Martin, primary, Dupic, Laurent, primary, Morelle, Guillaume, primary, Abou Chahla, Wadih, primary, Barlogis, Vincent, primary, Bertrand, Yves, primary, Bruno, Bénédicte, primary, Jeziorski, Eric, primary, Paillard, Catherine, primary, Rohrlich, Pierre Simon, primary, Stephan, Jean Louis, primary, Thomas, Caroline, primary, Chhun, Stéphanie, primary, Pellier, Isabelle, primary, Marie-Cardine, Aude, primary, Fusaro, Mathieu, primary, de Saint Basile, Genevieve, primary, Picard, Capucine, primary, Elie, Caroline, primary, Neven, Benedicte, primary, Blanche, Stephane, primary, and Fischer, Alain, primary
- Published
- 2019
- Full Text
- View/download PDF
41. Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
- Author
-
Rakotonjanahary, Josué, primary, Gravier, Nicolas, additional, Lambron, Julien, additional, De Carli, Emilie, additional, Toulgoat, Frédérique, additional, Delion, Matthieu, additional, Pellier, Isabelle, additional, and Rialland, Xavier, additional
- Published
- 2019
- Full Text
- View/download PDF
42. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
- Author
-
Gilardin, Laurent, Delignat, Sandrine, Peyron, Ivan, Ing, Mathieu, Lone, Yu-Chun, Gangadharan, Bagirath, Michard, Baptiste, Kherabi, Yousra, Sharma, Meenu, Pashov, Anastas, Toutirais, Olivier, Loiseau, Pascale, Veyradier, Agnès, Kaveri, Srini, Maillere, Bernard, Coppo, Paul, Lacroix-Desmazes, Sébastien, Chatillon, Jean-François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean-Baptiste, Musette, Philippe, Coignard-Biehler, Hélène, Mahlaoui, Nizar, Pilmis, Benoit, Barlogis, Vincent, Brosselin, Pauline, de Vergnes, Nathalie, Debré, Marianne, Malphettes, Marion, Frange, Pierre, Catherinot, Emilie, Pellier, Isabelle, Durieu, Isabelle, Perlat, Antoinette, Royer, Bruno, Le Quellec, Alain, Jeziorski, Eric, Fischer, Alain, Lortholary, Olivier, Aaron+, Laurent, Adoue, Daniel, Aguilar, Claire, Aladjidi, Nathalie, Alcaïs, Alexandre, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Bayart, Sophie, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphael, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Cohen-Beaussant, Sarah, Costes, Laurence, Couderc, Louis-Jean, Cougoul, Pierre, Courteille, Virginie, de Saint Basile, Geneviève, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Doré, Eric, Dulieu, Fabienne, Edan, Christine, Entz-Werlé, Natacha, Fieschi, Claire, Forestier, Amandine, Fouyssac, Fanny, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Hermine, Olivier, Hoarau, Cyrille, Humbert, Sebastien, Jaccard, Arnaud, Jacquot, Serge, Jais, Jean-Philippe, Jaussaud, Roland, Jeandel, Pierre-Yves, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Lascaux, Anne-Sophie, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefèvre, Guillaume, Lemal, Richard, Te, Valérie Li Thiao, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Oudot, Caroline, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Perel, Yves, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Provot, Johan, Quartier, Pierre, Rieux-Laucat, Frédéric, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Rubié, Hervé, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Tron, François, Viallard, Jean-François, Roux, Clément, Tifratene, K, Socie, G., Galambrun, C., Bertrand, Yves, Rialland, F., Jubert, C, Pochon, C, Paillard, C., Sirvent, A., Nelken, B., Vannier, Jean-Pierre, Freycon, C, Beguin, Y, Raus, N, Yakoub-Agha, I., Mohty, M., Dalle, J-H, Michel, Gérard, Pradier, C., Peffault de Latour, R., Rohrlich, P-S, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Greffes d'Epitheliums et Regulation de l'Activation Lymphocytaire, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Institut Stephan Angeloff, Réseau International des Instituts Pasteur (RIIP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Biologique [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unité d'Immunologie Hématologie et Rhumatologie Pédiatrique [Necker, Paris], Hôpital Foch [Suresnes], Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Collège de France - Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service d'Hémato-oncologie Pédiatrique, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Tronche, Département d'Immunologie, hématologie et rhumatologie pédiatriques [Hôpital Necker-Enfants malades - APHP], Hématogoie pédiatrique, hôpital Sud, Laboratoire de Mathématiques Nicolas Oresme (LMNO), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses, CHU Grenoble, Service de Pédiatrie Médicale [Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Trousseau [APHP], Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département d'Oncologie Pédiatrique [CHU Hautepierre, Strasbourg], Hôpital de Hautepierre [Strasbourg], Immunologie clinique [CHU St-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'Hématologie et d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent [CHU Rennes], Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT), Ecole Polytechnique Fédérale de Lausanne (EPFL), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Service d'informatique médicale et biostatistiques [CHU Necker], Université de Reims Champagne-Ardenne (URCA), Institut d’Hémato-Oncologie Pédiatrique, Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), service de Médecine Interne et d'Immunologie Clinique [AP-HP Hôpital Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Internal Medicine, Paris, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Catalysis, Synthesis of Biomolecules and Sustainable Development (CSB2D), Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistique et de Recherche Clinique (UBRC), Dept of Physiology, McGill University = Université McGill [Montréal, Canada], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut Jean Godinot [Reims], UNICANCER, Service d'Immunopathologie Clinique, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Service Immuno Hémato-Onco Pédiatrique, Sercice Hématologie, immunologie et oncologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service Hématologie Infantile, Immunogenetics of pediatric autoimmune diseases (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'Hématologie et d'Oncologie pédiatrique, Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Service de pneumologie pédiatrique, Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Médecine Interne, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Pediatrie Debrousse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Combustion, Aérothermique, Réactivité et Environnement (ICARE), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS - CNRS), Service d'Hématologie et d'Oncologie Médicale, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service d'hémato-immuno-oncologie pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Etablissement français du sang [Poitiers] (EFS), Public Health Department, Hôpital de l'Archet, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Innate immunity and Immunotherapy (CRCINA - Département INCIT - Equipe 7), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de médecine interne, Hôpital Universitaire d'Amiens, CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Service de médecine interne, hôpital Purpan, Hôpital Sud, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et Neurobiologie intégrée (NutriNeur0), Ecole nationale supérieure de chimie, biologie et physique-Institut Polytechnique de Bordeaux-Université Sciences et Technologies - Bordeaux 1-Institut National de la Recherche Agronomique (INRA)-Université Bordeaux Segalen - Bordeaux 2, Service d’oncologie hématologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent, CHU Pontchaillou [Rennes]-Hôpital Sud, Apoptose et Progression tumorale (CRCNA / Equipe 9), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Lille Inflammation Research International Center (LIRIC), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), CHU Toulouse [Toulouse]-Hôpital de Rangueil, Institute of Chemistry for Life and Health Sciences (i-CLEHS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), McGill University, Institut Jean Godinot, CRLCC Jean Godinot, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hématologie pédiatrique, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA), Unité d'Hémato-Oncologie, Hôpital des Enfants, CHU Saint-Etienne, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS), CHU Saint-Antoine [APHP], École pratique des hautes études (EPHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Chaire Médecine expérimentale (A. Fischer), Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Pontchaillou [Rennes]-hôpital Sud, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
- Subjects
Oncology ,medicine.medical_specialty ,Palliative care ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Hematopoietic stem cell transplantation ,Donor lymphocyte infusion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Treatment Failure ,Child ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Transplantation ,Acute leukemia ,Chemotherapy ,Leukemia ,business.industry ,Palliative Care ,Hematopoietic Stem Cell Transplantation ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Donor Lymphocytes ,Leukemia, Biphenotypic, Acute ,3. Good health ,Surgery ,Survival Rate ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Lymphocyte Transfusion ,030220 oncology & carcinogenesis ,Acute Disease ,Disease Progression ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (SCT) contributes to improved outcome in childhood acute leukemia (AL). However, therapeutic options are poorly defined in the case of post-transplantation relapse. We aimed to compare treatment strategies in 334 consecutive children with acute leukemia relapse or progression after SCT in a recent 10-year period. Data could be analyzed in 288 patients (157 ALL, 123 AML and 8 biphenotypic AL) with a median age of 8.16 years at transplantation. The median delay from first SCT to relapse or progression was 182 days. The treatment consisted of chemotherapy alone (n=108), chemotherapy followed by second SCT (n=70), supportive/palliative care (n=67), combination of chemotherapy and donor lymphocyte infusion (DLI; n=30), or isolated reinfusion of donor lymphocytes (DLI; n=13). The median OS duration after relapse was 164 days and differed according to therapy: DLI after chemotherapy=385 days, second allograft=391 days, chemotherapy=174 days, DLI alone=140 days, palliative care=43 days. A second SCT or a combination of chemotherapy and DLI yielded similar outcome (hazard ratio (HR)=0.85, P=0.53) unlike chemotherapy alone (HR=1.43 P=0.04), palliative care (HR=4.24, P
- Published
- 2017
- Full Text
- View/download PDF
43. CD21 deficiency in two siblings with recurrent respiratory infections and hypogammaglobulinemia
- Author
-
Rosain, Jeremie, Miot, Charline, Lambert, Nathalie, Rousselet, Marie-Christine, Pellier, Isabelle, Picard, Capucine, Picard, Capucine, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Unité d'Immuno-Hémato-Oncologie Pédiatrique [Angers], PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Département de Pathologie Cellulaire et Tissulaire [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), Plateforme de génomique [SFR Necker], Structure Fédérative de Recherche Necker (SFR Necker - UMS 3633 / US24), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), no source, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Centre Hospitalier Universitaire d'Angers, Université d'Angers ( UA ) -CHU Angers, Structure Fédérative de Recherche Necker ( SFR Necker - UMS 3633 / US24 ), and Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Assistance publique - Hôpitaux de Paris (AP-HP)
- Subjects
respirat ory infections ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,[ SDV.IMM ] Life Sciences [q-bio]/Immunology ,CD21 ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Primary antibody deficiency ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; no abstract
- Published
- 2017
- Full Text
- View/download PDF
44. Persistent osteoarticular pain in children: early clinical and laboratory findings suggestive of acute lymphoblastic leukemia (a multicenter case-control study of 147 patients).
- Author
-
Louvigné, Mathilde, Rakotonjanahary, Josué, Goumy, Laurence, Tavenard, Aude, Brasme, Jean-François, Rialland, Fanny, Baruchel, André, Auclerc, Marie-Françoise, Despert, Véronique, Desgranges, Marie, Jean, Sylvie, Faye, Albert, Meinzer, Ulrich, Lorrot, Mathie, Job-Deslandre, Chantal, Bader-Meunier, Brigitte, Gandemer, Virginie, Pellier, Isabelle, on behalf of the GOCE Group, and De Carli, Emilie
- Subjects
LYMPHOBLASTIC leukemia ,CHRONIC pain ,ACUTE leukemia ,BONE marrow examination ,JUVENILE idiopathic arthritis ,LYMPHADENITIS - Abstract
Background: The aim of this study was to identify early clinical and laboratory features that distinguish acute lymphoblastic leukemia (ALL) from juvenile idiopathic arthritis (JIA) in children presenting with persistent bone or joint pain for at least 1 month. Methods: We performed a multicenter case-control study and reviewed medical records of children who initially presented with bone or joint pain lasting for at least 1 month, all of whom were given a secondary diagnosis of JIA or ALL, in four French University Hospitals. Each patient with ALL was paired by age with two children with JIA. Logistic regression was used to compare clinical and laboratory data from the two groups. Results: Forty-nine children with ALL and 98 with JIA were included. The single most important feature distinguishing ALL from JIA was the presence of hepatomegaly, splenomegaly or lymphadenopathy; at least one of these manifestations was present in 37 cases with ALL, but only in 2 controls with JIA, for an odds ratio (OR) of 154 [95%CI: 30–793] (regression coefficient: 5.0). If the presence of these findings is missed or disregarded, multivariate analyses showed that non-articular bone pain and/or general symptoms (asthenia, anorexia or weight loss) (regression coefficient: 4.8, OR 124 [95%CI: 11.4–236]), neutrophils < 2 × 10
9 /L (regression coefficient: 3.9, OR 50 [95%CI: 4.3–58]), and platelets < 300 × 109 /L (regression coefficient: 2.6, OR 14 [95%CI: 2.3–83.9]) were associated with the presence of ALL (area under the ROC curve: 0.96 [95%CI: 0.93–0.99]). Conclusions: Based on our findings we propose the following preliminary decision tree to be tested in prospective studies: in children presenting with at least 1 month of osteoarticular pain and no obvious ALL in peripheral smear, perform a bone marrow examination if hepatomegaly, splenomegaly or lymphadenopathy is present. If these manifestations are absent, perform a bone marrow examination if there is fever or elevated inflammatory markers associated with non-articular bone pain, general symptoms (asthenia, anorexia or weight loss), neutrophils < 2 × 109 /L or platelets < 300 × 109 /L. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
45. Treatment with cyclosporin in auto‐immune cytopenias in children: The experience from the French cohort OBS'CEREVANCE
- Author
-
Penel‐Page, Mathilde, primary, Bertrand, Yves, additional, Fernandes, Helder, additional, Kherfellah, Djamel, additional, Leverger, Guy, additional, Leblanc, Thierry, additional, Libbrecht, Clara, additional, Michel, Gérard, additional, Jeziorski, Eric, additional, Armari‐Alla, Corinne, additional, Nelken, Brigitte, additional, Pellier, Isabelle, additional, Pasquet, Marlène, additional, Perel, Yves, additional, and Aladjidi, Nathalie, additional
- Published
- 2018
- Full Text
- View/download PDF
46. A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
- Author
-
Pasquet,Marlène, Pellier,Isabelle, Aladjidi,Nathalie, Auvrignon,Anne, Cherin,Patrick, Clerson,Pierre, Cozon,Grégoire, Jaussaud,Roland, Bienvenu,Boris, Hoarau,Cyrille, Pasquet,Marlène, Pellier,Isabelle, Aladjidi,Nathalie, Auvrignon,Anne, Cherin,Patrick, Clerson,Pierre, Cozon,Grégoire, Jaussaud,Roland, Bienvenu,Boris, and Hoarau,Cyrille
- Abstract
Marlène Pasquet,1 Isabelle Pellier,2 Nathalie Aladjidi,3 Anne Auvrignon,4 Patrick Cherin,5 Pierre Clerson,6 Gregoire Jacques Noël Cozon,7 Roland Jaussaud,8 Boris Bienvenu,9 Cyrille Hoarau10 1Pediatric Hematology and Oncology Department, University Hospital Centre of Toulouse, Toulouse, 2University Hospital of Angers, Angers, 3Paediatric Hematology Unit, CEREVANCE, CIC 1401, Inserm CICP, Hospital Pellegrin, 4Trousseau Hospital, 5Internal Medicine Department, Paris, 6Soladis Clinical Studies, Roubaix, 7Clinical Immunology, Edouard Herriot Hospital, Lyon, 8Internal Medicine and Clinical Immunology Department, University Hospital Centre of Nancy, Nancy, 9Internal Medicine Department, University Hospital Centre of Caen, Caen, 10Renal Transplantation and Clinical immunology Department, University Hospital Centre of Tours, Tours, France Objective: To assess quality of life and satisfaction regarding immunoglobulin-replacement therapy (IgRT) treatment according to the route (intravenous Ig [IVIg] or subcutaneous Ig [SCIg]) and place of administration (home-based IgRT or hospital-based IgRT).Subjects and methods: Children 5–15 years old treated for primary immunodeficiency disease (PIDD) with IgRT for ≥3 months were included in a prospective, noninterventional cohort study and followed over 12 months. Quality of life was assessed with the Child Health Questionnaire – parent form (CHQ-PF)-50 questionnaire. Satisfaction with IgRT was measured with a three-dimensional scale (Life Quality Index [LQI] with three components: factor I [FI], treatment interference; FII, therapy-related problems; FIII, therapy settings).Results: A total of 44 children (9.7±3.2 years old) receiving IgRT for a mean of 5.6±4.5 years (median 4.1 years) entered the study: 18 (40.9%) were receiving hospital-based IVIg, two (4.6%) were receiving home-based IVIg, and 24 (54.6%) were treated by home-based SCIg. LQI FIII was higher for home-b
- Published
- 2017
47. Mutations in SRP54 Gene Cause Severe Primary Neutropenia As Well As Shwachman-Diamond-like Syndrome
- Author
-
Bellanné-Chantelot, Christine, primary, Marty, Caroline, additional, Schmaltz-Panneau, Barbara, additional, Fenneteau, Odile, additional, Callebaut, Isabelle, additional, Clauin, Séverine, additional, Docet, Aurélie, additional, Damaj, Gandhi, additional, Leblanc, Thierry, additional, Pellier, Isabelle, additional, Stoven, Cécile, additional, Souquere, Sylvie, additional, Antony-Debre, Iléana, additional, Beaupain, Blandine, additional, Aladjidi, Nathalie, additional, Barlogis, Vincent, additional, Bauduer, Frederic, additional, Bensaid, Philippe, additional, Boesflug-Tanguy, Odile, additional, Berger, Claire, additional, Bertrand, Yves, additional, Carausu, Liana, additional, Fieschi, Claire, additional, Galambrun, Claire, additional, Schmidt, Aline, additional, Journel, Hubert, additional, Mazingue, Francoise, additional, Nelken, Brigitte, additional, Quah, Thuan Chong, additional, Oksenhendler, Eric, additional, Ouachee, Marie, additional, Pasquet, Marlène, additional, Suarez, Felipe, additional, Pierron, Gérard, additional, Vainchenker, William, additional, Plo, Isabelle, additional, and Donadieu, Jean, additional
- Published
- 2017
- Full Text
- View/download PDF
48. A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
- Author
-
Pasquet, Marlène, primary, Pellier, Isabelle, additional, Aladjidi, Nathalie, additional, Auvrignon, Anne, additional, Cherin, Patrick, additional, Clerson, Pierre, additional, Cozon, Grégoire, additional, Jaussaud, Roland, additional, Bienvenu, Boris, additional, and Hoarau, Cyrille, additional
- Published
- 2017
- Full Text
- View/download PDF
49. Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP)
- Author
-
Roche, Ombeline, primary, Aladjidi, Nathalie, additional, Rakotonjanahary, Josué, additional, Leverger, Guy, additional, Leblanc, Thierry, additional, Thomas, Caroline, additional, Pasquet, Marlène, additional, Courcoux, Mary‐France, additional, Bayart, Sophie, additional, Gilibert‐Yvert, Marion, additional, Neven, Bénédicte, additional, Quartier, Pierre, additional, and Pellier, Isabelle, additional
- Published
- 2017
- Full Text
- View/download PDF
50. Pharmacokinetic and Pharmacodynamic Characterization of Graspa Versus Native L-Asparaginase in Combination with Cooprall Chemotherapy in a Phase 3 Randomized Trial for the Treatment of Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01 51851 7)
- Author
-
Thomas, Xavier, Bertrand, Yves, Baruchel, Andre, Blin, Nicolas, Tavernier, Emmanuelle, Ducassou, Stephane, Norbert Vey, Gandemer, Virginie, Cacheux, Victoria, Mazingue, Francoise, Raffoux, Emmanuel, Plat, Genevieve, Fernandes, Jose, Poiree, Maryline, Fornecker, Luc, Stephan, Jean-Louis, Hunault, Mathilde, Auvrignon, Anne, Leguay, Thibault, Lepretre, Stephane, Ferster, Alina, Pellier, Isabelle, Plouvier, Emmanuel, Schmitt, Claudine, Bonin, Cecile, Godfrin, Yann, El Hariry, Iman, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Hématologie et immunologie pédiatrique, Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME), Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pellegrin Tripode, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Pediatric Onco-Hematology Unit, CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Clermont-Ferrand, Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pédiatrie, Unité d'Oncologie et Hématologie Pédiatrique, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hématologie pédiatrique, CHU Saint-Etienne, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Hématologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
WOS:000368020102004; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.